Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01722149
Other study ID # FAPME-1
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date February 19, 2015
Est. completion date July 18, 2019

Study information

Verified date August 2019
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MPM patients are not eligible for surgical procedures like decortication or pleuro-pneumectomy and have a median survival of 12 months with palliative chemotherapy. Therefore, new therapeutic approaches are of crucial need in this clinical situation. This is a phase I trial for patients with malignant pleural mesothelioma with pleural effusion testing the safety of a fixed single dose of 1x10e6 adoptively transferred FAP-specific re-directed T cells given directly in the pleural effusion. Lymphocytes will be taken 21 days before transfer from peripheral blood. CD8 positive T cells will be isolated and re-programmed by retroviral transfer of a chimeric antigen receptor (CAR) recognizing FAP which serves as target structure in MPM.

- Trial with immunomodulatory product / biological


Description:

This is a phase I trial for patients with malignant pleural mesothelioma. A fixed single dose of adoptively transferred FAP-specific CD8 positive re-directed T cells will be given in the pleural effusion.

Three patients who are at the time point of screening not operable will be treated with re-directed T cells administered into the pleural effusion after completion of 3 cycles of palliative chemotherapy. In the case of one AE grade III/IV or one SAE - and the occurrence of DLT both judged to be treatment related by an independent safety monitoring board - the patient number will be expanded to 6 patients. The study will be stopped if one additional DLT occurs also judged to be treatment related.

Patients will be treated with 1x10e6 re-directed FAP-specific T cells injected in the pleural effusion. The study ends 35 days after adoptive T cell transfer. Re-directed FAP-specific T cells will be administered at day 0 (day 14 of the third cycle of palliative chemotherapy). The study is designed to demonstrate safety of 1x10e6 re-directed FAP-specific T cells. The next patient will be enrolled earliest, when the previous patient completed day +14 and the safety monitoring board has not declared any DLTs. The palliative chemotherapy is not part of the study protocol.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date July 18, 2019
Est. primary completion date March 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria:

- Histologically or cytologically confirmed and documented malignant pleural mesothelioma with pleural effusion,

- Signed Informed Consent after being informed,

- Patients medically and/or functionally at screening not accessible for surgical treatment

- Bone marrow function: hemoglobin >/= 100 g/L; white blood cell count (WBC) >/= 1.0 x 109/L; absolute neutrophile count (ANC) >/= 0.5 x 109/L; platelet count >/= 100 x 109/L,

- Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) </= 2.5 times upper limit of normal (ULN)); bilirubin </= 1.5 x ULN,

- Renal: creatinine = 176 umol/l and creatinine clearance = 45 mL/min,

- No concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents,

- The patient has received no major organ allograft,

- HIV-negative,

- HBV and HCV negative,

- No uncontrolled bleeding disorder,

- Patients of child-producing potential must agree to use contraception while enrolled in the study and for 24 months after the adoptive transfer.

Exclusion criteria:

- Contra-indications to the class of TpP, e.g. known hypersensitivity or allergy to the investigational product,

- Contra-indications on ethical grounds,

- Women who are pregnant or breast feeding,

- Intention to become pregnant during the course of the study,

- Lack of safe contraception: Safe contraception is defined as follows:Female and male subjects of childbearing potential, using and willing to continue using a medically reliable method of double barrier contraception for the entire study duration and the next 2 years, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices in combination with preservatives. Or subjects who are using any other method considered sufficiently reliable by the investigator in individual cases.Subjects who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.

- Known or suspected non-compliance, drug or alcohol abuse

- Pericardial effusion of more than 100 ml. Pericardial involvement assessed by CT scan

- Patients with medical history of coronary heart disease (CHD), stroke or peripheral vascular disease (PVD),

- Patients with medical history of autoimmune disease such as multiple sclerosis, lupus, rheumatoid arthritis, inflammatory bowel disease or small vessel vasculitis,

- Regular intake of immune-modulating drugs,

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state of the subject,

- Participation in another study with investigational drug within the 30 days preceding and during the present study,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent persons.

Study Design


Intervention

Genetic:
Adoptive Transfer of re-directed T cells
Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion

Locations

Country Name City State
Switzerland University Hospital Zurich, Division of Oncology Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (2)

Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012 Dec 22;12:615. doi: 10.1186/1471-2407-12-615. — View Citation

Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013 Aug 12;11:187. doi: 10.1186/1479-5876-11-187. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Incidence and severity of treatment-related laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version v4.03 criteria as grade III-IV. In the case of one AE grade III/IV or one SAE the safety monitoring board will judge whether the case is treatment related and whether it have to be counted as DLT. until 35 days after transfer of re-directed T cells
See also
  Status Clinical Trial Phase
Recruiting NCT06037941 - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma N/A
Completed NCT01675765 - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Phase 1
Withdrawn NCT04201145 - Pembrolizumab + Defactinib In Pleural Mesothelioma Phase 1
Completed NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Phase 2
Completed NCT02369198 - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Phase 1
Terminated NCT01870609 - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT00886028 - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00272558 - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT02436733 - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM Phase 2
Completed NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment
Completed NCT01721018 - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Phase 1/Phase 2
Active, not recruiting NCT00797719 - Short Neoadjuvant Hemithoracic IMRT for MPM Phase 1/Phase 2
Completed NCT00386815 - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04775446 - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed NCT01644994 - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT01865045 - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed NCT00571298 - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Phase 1
Recruiting NCT01343264 - Trimodality Therapy for Malignant Pleural Mesothelioma N/A
Active, not recruiting NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Phase 1